United Therapeutics Co. (NASDAQ:UTHR) Director Louis W. Sullivan Sells 26,209 Shares

United Therapeutics Co. (NASDAQ:UTHR) Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Stock Performance

NASDAQ UTHR traded up $2.61 during trading hours on Thursday, hitting $360.16. The company had a trading volume of 335,081 shares, compared to its average volume of 446,780. The business has a 50 day moving average of $370.89 and a 200-day moving average of $344.26. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The company has a market cap of $16.08 billion, a PE ratio of 15.82, a price-to-earnings-growth ratio of 1.05 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same quarter last year, the business posted $5.38 EPS. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. Sell-side analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Argus boosted their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH increased their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group boosted their target price on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the business. ClariVest Asset Management LLC boosted its stake in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the period. USA Financial Formulas acquired a new stake in shares of United Therapeutics during the third quarter worth about $33,000. Brooklyn Investment Group acquired a new stake in shares of United Therapeutics during the third quarter worth about $33,000. Innealta Capital LLC purchased a new position in shares of United Therapeutics during the second quarter worth about $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in United Therapeutics during the 3rd quarter valued at approximately $82,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.